276 related articles for article (PubMed ID: 33411954)
1. Analysis of nonleukemic cellular subcompartments reconstructs clonal evolution of acute myeloid leukemia and identifies therapy-resistant preleukemic clones.
Saeed BR; Manta L; Raffel S; Pyl PT; Buss EC; Wang W; Eckstein V; Jauch A; Trumpp A; Huber W; Ho AD; Lutz C
Int J Cancer; 2021 Jun; 148(11):2825-2838. PubMed ID: 33411954
[TBL] [Abstract][Full Text] [Related]
2. Acute myeloid leukemia derived from lympho-myeloid clonal hematopoiesis.
Thol F; Klesse S; Köhler L; Gabdoulline R; Kloos A; Liebich A; Wichmann M; Chaturvedi A; Fabisch J; Gaidzik VI; Paschka P; Bullinger L; Bug G; Serve H; Göhring G; Schlegelberger B; Lübbert M; Kirchner H; Wattad M; Kraemer D; Hertenstein B; Heil G; Fiedler W; Krauter J; Schlenk RF; Döhner K; Döhner H; Ganser A; Heuser M
Leukemia; 2017 Jun; 31(6):1286-1295. PubMed ID: 27881874
[TBL] [Abstract][Full Text] [Related]
3. Persistence of pre-leukemic clones during first remission and risk of relapse in acute myeloid leukemia.
Rothenberg-Thurley M; Amler S; Goerlich D; Köhnke T; Konstandin NP; Schneider S; Sauerland MC; Herold T; Hubmann M; Ksienzyk B; Zellmeier E; Bohlander SK; Subklewe M; Faldum A; Hiddemann W; Braess J; Spiekermann K; Metzeler KH
Leukemia; 2018 Jul; 32(7):1598-1608. PubMed ID: 29472724
[TBL] [Abstract][Full Text] [Related]
4. Therapy-related acute myeloid leukemia developing 14 years after allogeneic hematopoietic stem cell transplantation, from a persistent R882H-DNMT3A mutated clone of patient origin.
Martín I; Navarro B; Villamón E; Solano C; Serrano A; Calabuig M; Amat P; Domingo F; Abellán R; García F; Olivares MD; Chaves FJ; Tormo M; Hernández-Boluda JC
Exp Mol Pathol; 2018 Aug; 105(1):139-143. PubMed ID: 30017658
[TBL] [Abstract][Full Text] [Related]
5. Clonal evolution of preleukemic hematopoietic stem cells precedes human acute myeloid leukemia.
Jan M; Snyder TM; Corces-Zimmerman MR; Vyas P; Weissman IL; Quake SR; Majeti R
Sci Transl Med; 2012 Aug; 4(149):149ra118. PubMed ID: 22932223
[TBL] [Abstract][Full Text] [Related]
6. DNMT3A mutations promote anthracycline resistance in acute myeloid leukemia via impaired nucleosome remodeling.
Guryanova OA; Shank K; Spitzer B; Luciani L; Koche RP; Garrett-Bakelman FE; Ganzel C; Durham BH; Mohanty A; Hoermann G; Rivera SA; Chramiec AG; Pronier E; Bastian L; Keller MD; Tovbin D; Loizou E; Weinstein AR; Gonzalez AR; Lieu YK; Rowe JM; Pastore F; McKenney AS; Krivtsov AV; Sperr WR; Cross JR; Mason CE; Tallman MS; Arcila ME; Abdel-Wahab O; Armstrong SA; Kubicek S; Staber PB; Gönen M; Paietta EM; Melnick AM; Nimer SD; Mukherjee S; Levine RL
Nat Med; 2016 Dec; 22(12):1488-1495. PubMed ID: 27841873
[TBL] [Abstract][Full Text] [Related]
7. Mutant DNA methylation regulators endow hematopoietic stem cells with the preleukemic stem cell property, a requisite of leukemia initiation and relapse.
Tan Y; Liu H; Chen S
Front Med; 2015 Dec; 9(4):412-20. PubMed ID: 26482067
[TBL] [Abstract][Full Text] [Related]
8. Quantitative detection of DNMT3A R882H mutation in acute myeloid leukemia.
Berenstein R; Blau IW; Suckert N; Baldus C; Pezzutto A; Dörken B; Blau O
J Exp Clin Cancer Res; 2015 May; 34(1):55. PubMed ID: 25994761
[TBL] [Abstract][Full Text] [Related]
9. Preleukemic mutations in human acute myeloid leukemia affect epigenetic regulators and persist in remission.
Corces-Zimmerman MR; Hong WJ; Weissman IL; Medeiros BC; Majeti R
Proc Natl Acad Sci U S A; 2014 Feb; 111(7):2548-53. PubMed ID: 24550281
[TBL] [Abstract][Full Text] [Related]
10. IDH1/2 but not DNMT3A mutations are suitable targets for minimal residual disease monitoring in acute myeloid leukemia patients: a study by the Acute Leukemia French Association.
Debarri H; Lebon D; Roumier C; Cheok M; Marceau-Renaut A; Nibourel O; Geffroy S; Helevaut N; Rousselot P; Gruson B; Gardin C; Chretien ML; Sebda S; Figeac M; Berthon C; Quesnel B; Boissel N; Castaigne S; Dombret H; Renneville A; Preudhomme C
Oncotarget; 2015 Dec; 6(39):42345-53. PubMed ID: 26486081
[TBL] [Abstract][Full Text] [Related]
11. Identification of Cell Type-Specific Effects of
Bae SG; Kim HJ; Kim MY; Kim DDH; Shin SI; Ahn JS; Park J
Mol Cells; 2023 Oct; 46(10):611-626. PubMed ID: 37853686
[TBL] [Abstract][Full Text] [Related]
12. A common ancestral DNMT3A-mutated preleukemic clone giving rise to AML and MDS in an adolescent girl.
Göhring G; Thomay K; Schmidt G; Ripperger T; Xu M; Wittner N; Chao MM; Baumann I; Niewisch M; Reinhardt D; Klingebiel T; Thol F; Schlegelberger B; Niemeyer CM
Leuk Lymphoma; 2017 Mar; 58(3):718-721. PubMed ID: 27892742
[No Abstract] [Full Text] [Related]
13. Normal hematopoietic stem cells within the AML bone marrow have a distinct and higher ALDH activity level than co-existing leukemic stem cells.
Schuurhuis GJ; Meel MH; Wouters F; Min LA; Terwijn M; de Jonge NA; Kelder A; Snel AN; Zweegman S; Ossenkoppele GJ; Smit L
PLoS One; 2013; 8(11):e78897. PubMed ID: 24244383
[TBL] [Abstract][Full Text] [Related]
14. Cellular distribution of IDH mutations in AML during morphologic remission.
Ramanan R; Tiong IS; Ivey A; Ong DM; Brown FC; Chua C; Das T; Curtis DJ
Leuk Res; 2023 Jan; 124():106993. PubMed ID: 36459762
[TBL] [Abstract][Full Text] [Related]
15. EZH2, new diagnosis and prognosis marker in acute myeloid leukemia patients.
Mechaal A; Menif S; Abbes S; Safra I
Adv Med Sci; 2019 Sep; 64(2):395-401. PubMed ID: 31331874
[TBL] [Abstract][Full Text] [Related]
16. Genomic landscape and clonal evolution of acute myeloid leukemia with t(8;21): an international study on 331 patients.
Christen F; Hoyer K; Yoshida K; Hou HA; Waldhueter N; Heuser M; Hills RK; Chan W; Hablesreiter R; Blau O; Ochi Y; Klement P; Chou WC; Blau IW; Tang JL; Zemojtel T; Shiraishi Y; Shiozawa Y; Thol F; Ganser A; Löwenberg B; Linch DC; Bullinger L; Valk PJM; Tien HF; Gale RE; Ogawa S; Damm F
Blood; 2019 Mar; 133(10):1140-1151. PubMed ID: 30610028
[TBL] [Abstract][Full Text] [Related]
17. Monitoring of clonal evolution of double C-KIT exon 17 mutations by Droplet Digital PCR in patients with core-binding factor acute myeloid leukemia.
Tan Y; Liu Z; Wang W; Zhu G; Guo J; Chen X; Zheng C; Xu Z; Chang J; Ren F; Wang H
Leuk Res; 2018 Jun; 69():89-93. PubMed ID: 29705537
[TBL] [Abstract][Full Text] [Related]
18. Evolution of Cytogenetically Normal Acute Myeloid Leukemia During Therapy and Relapse: An Exome Sequencing Study of 50 Patients.
Greif PA; Hartmann L; Vosberg S; Stief SM; Mattes R; Hellmann I; Metzeler KH; Herold T; Bamopoulos SA; Kerbs P; Jurinovic V; Schumacher D; Pastore F; Bräundl K; Zellmeier E; Ksienzyk B; Konstandin NP; Schneider S; Graf A; Krebs S; Blum H; Neumann M; Baldus CD; Bohlander SK; Wolf S; Görlich D; Berdel WE; Wörmann BJ; Hiddemann W; Spiekermann K
Clin Cancer Res; 2018 Apr; 24(7):1716-1726. PubMed ID: 29330206
[No Abstract] [Full Text] [Related]
19. Genomic profiling and directed ex vivo drug analysis of an unclassifiable myelodysplastic/myeloproliferative neoplasm progressing into acute myeloid leukemia.
Hyrenius-Wittsten A; Sturesson H; Bidgoli M; Jonson T; Ehinger M; Lilljebjörn H; Scheding S; Andersson AK
Genes Chromosomes Cancer; 2016 Nov; 55(11):847-54. PubMed ID: 27240832
[TBL] [Abstract][Full Text] [Related]
20. Persistent DNMT3A mutation burden in DNMT3A mutated adult cytogenetically normal acute myeloid leukemia patients in long-term remission.
Sun Y; Shen H; Xu T; Yang Z; Qiu H; Sun A; Chen S; Wu D; Xu Y
Leuk Res; 2016 Oct; 49():102-7. PubMed ID: 27626217
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
